MAJOR DEPRESSIVE DISORDER (MDD)
SCF-RDOS INDICATION REGISTRY ENTRY
Classification
Category | Classification |
Clinical Domain | Depressive Disorders |
DSM-5-TR Classification | Major Depressive Disorder |
ICD-11 Classification | Depressive Episode / Recurrent Depressive Disorder |
SCF-RDOS Domain | Neuropsychiatric, Affective, Cognitive, Neuroendocrine, Behavioral |
Primary Functional Systems | Mood Regulation, Reward Processing, Stress Response, Cognitive Function, Neuroplasticity |
Pathophysiological Classification | Multisystem Mood-Regulation and Neuroplasticity Dysfunction Syndrome |
Typical Age of Onset | Adolescence through Late Adulthood |
Clinical Course | Episodic, Recurrent, Chronic, Progressive |
Severity Spectrum | Mild → Moderate → Severe → Severe with Psychotic Features |
Functional Impact | Emotional, Cognitive, Social, Occupational, Physical |
DEFINITION
MAJOR DEPRESSIVE DISORDER (MDD) is a common and serious mood disorder characterized by persistent depressed mood and/or markedly diminished interest or pleasure in activities, accompanied by cognitive, emotional, behavioral, vegetative, and physical symptoms that cause clinically significant distress or impairment.
The disorder affects multiple domains including motivation, reward processing, cognition, sleep, appetite, energy regulation, emotional resilience, social functioning, and occupational performance. Episodes typically persist for weeks to months and may recur throughout life.
Within the SCF-RDOS framework, Major Depressive Disorder is conceptualized as a multisystem affective disorder involving dysfunction across reward-processing networks, emotional-regulation circuits, neuroplasticity systems, stress-response architecture, neuroimmune pathways, and cognitive-control mechanisms.
ETIOPATHOGENIC CORE
Primary Pathogenic Theme
Genetic susceptibility, chronic stress exposure, neurobiological dysregulation, neuroinflammatory activation, impaired neuroplasticity, and maladaptive cognitive-emotional processing converge to produce sustained depressive symptomatology and progressive functional impairment.
Core Pathogenic Drivers
Domain | Contribution |
Reward-System Dysfunction | Anhedonia |
Stress-System Hyperactivation | Chronic depressive symptoms |
Neuroplasticity Impairment | Reduced adaptive recovery |
Neuroinflammation | Symptom amplification |
Cognitive Distortion Networks | Negative thinking patterns |
Emotional-Regulation Dysfunction | Persistent low mood |
Circadian Dysregulation | Sleep disturbances |
Social Disconnection | Functional deterioration |
SCF FAULT ARCHITECTURE
Tier 1 — Vulnerability and Predisposition Layer
Predisposing Factors
Potential contributors include:
- Family history of depression
- Genetic susceptibility
- Developmental trauma
- Childhood adversity
- Chronic stress exposure
- Medical illness
- Social isolation
- Personality vulnerabilities
- Sleep disorders
- Substance use disorders
Psychological Vulnerabilities
Common contributors include:
- Negative cognitive styles
- Low self-esteem
- Learned helplessness
- Perfectionism
- Emotional sensitivity
- Poor stress resilience
Tier 2 — Neurobiological and Psychological Dysregulation
Reward-System Dysfunction
Individuals may experience:
- Reduced pleasure responses
- Loss of motivation
- Reduced reward anticipation
- Diminished positive affect
- Behavioral disengagement
Stress-System Dysregulation
Manifestations may include:
Dysfunction | Consequence |
HPA-axis hyperactivation | Chronic stress burden |
Cortisol dysregulation | Mood impairment |
Neuroinflammation | Cognitive dysfunction |
Neuroplasticity reduction | Recovery impairment |
Circadian instability | Sleep disruption |
Tier 3 — Major Depressive Disorder Consolidation
Emotional Symptoms
Manifestations include:
- Persistent sadness
- Depressed mood
- Emotional numbness
- Hopelessness
- Worthlessness
- Excessive guilt
- Helplessness
- Reduced emotional responsiveness
Cognitive Symptoms
Manifestations include:
- Negative thinking
- Rumination
- Impaired concentration
- Memory difficulties
- Executive dysfunction
- Decision-making impairment
- Self-critical cognition
- Suicidal ideation (in some individuals)
Behavioral Symptoms
Manifestations include:
- Social withdrawal
- Reduced activity
- Behavioral passivity
- Reduced productivity
- Avoidance behaviors
- Loss of interest in previously enjoyable activities
Somatic Symptoms
Manifestations include:
- Fatigue
- Sleep disturbances
- Appetite changes
- Weight changes
- Psychomotor slowing or agitation
- Physical aches and pains
Tier 4 — Functional and Multisystem Decompensation
Potential outcomes include:
- Recurrent depressive episodes
- Occupational disability
- Academic impairment
- Relationship dysfunction
- Chronic health deterioration
- Substance misuse
- Increased medical morbidity
- Suicidality
- Reduced life expectancy
- Severe psychosocial impairment
MOLECULAR MULTI-OMICS PATHOGENESIS MAP
Genomics
Potential implicated systems:
- Serotonergic pathways
- Dopaminergic signaling systems
- Stress-response genes
- Neuroplasticity regulators
- Circadian-clock genes
Examples include:
- SLC6A4-associated pathways
- BDNF-related mechanisms
- HPA-axis regulatory genes
- Inflammatory susceptibility genes
Epigenomics
Potential alterations:
- Stress-induced methylation signatures
- Trauma-associated epigenetic remodeling
- Neuroplasticity-regulation changes
- Neuroimmune adaptations
Transcriptomics
Potential dysregulated pathways:
- Neurotrophic signaling
- Stress-response networks
- Reward-processing pathways
- Neuroimmune activation systems
Proteomics
Potential abnormalities:
- Brain-derived neurotrophic factor (BDNF)
- Inflammatory cytokines
- Synaptic proteins
- Stress-response mediators
Metabolomics
Potential disturbances:
- Serotonergic imbalance
- Dopaminergic dysfunction
- Glutamatergic dysregulation
- Cortisol abnormalities
- Mitochondrial-energy impairment
Interactomics
Potential network dysfunction:
- Stress–depression amplification loops
- Rumination-maintenance pathways
- Reward-deficiency cascades
- Neuroinflammation–mood interaction networks
Connectomics
Frequently implicated neural circuits:
Circuit | Functional Consequence |
Prefrontal Cortex | Executive dysfunction |
Anterior Cingulate Cortex | Emotional-regulation impairment |
Amygdala | Negative emotional bias |
Hippocampus | Memory and stress dysfunction |
Ventral Striatum | Anhedonia |
Default Mode Network | Rumination |
Frontolimbic Networks | Mood dysregulation |
Adapted from SCF multi-omic pathophysiology reconstruction principles.
PATHOGENESIS FLOW (SCF LOGIC)
Genetic and Environmental Vulnerability
↓
Chronic Stress and Neurobiological Dysregulation
↓
Reward-System Impairment
↓
Stress-System Hyperactivation
↓
Neuroplasticity Reduction
↓
Negative Cognitive Processing
↓
Behavioral Withdrawal
↓
Emotional Dysregulation
↓
Functional Decline
↓
Major Depressive Disorder
CLINICAL PRESENTATION
Core Symptoms
Mood Symptoms
- Persistent depressed mood
- Sadness
- Emptiness
- Emotional numbness
- Hopelessness
Anhedonia
- Loss of interest
- Loss of pleasure
- Reduced motivation
- Decreased engagement
Cognitive Symptoms
- Concentration difficulties
- Memory impairment
- Rumination
- Self-criticism
- Decision-making difficulties
- Suicidal thinking (when present)
Physical Symptoms
- Fatigue
- Sleep disturbance
- Appetite changes
- Weight fluctuation
- Reduced energy
- Psychomotor changes
Social and Functional Symptoms
- Social withdrawal
- Occupational dysfunction
- Relationship difficulties
- Reduced productivity
- Academic impairment
PATHOGENS → SYMPTOMATOLOGY → SCF FAULT TIER MAPPING
Pathogenic Driver | Clinical Manifestation | SCF Tier |
Vulnerability factors | Depression susceptibility | Tier 1 |
Reward-system dysfunction | Anhedonia | Tier 2 |
Neuroplasticity impairment | Persistent depressive symptoms | Tier 3 |
Functional decline | Disability and recurrence | Tier 4 |
ASSOCIATED CONDITIONS
Major Depressive Disorder commonly overlaps with:
- Generalized Anxiety Disorder
- Persistent Depressive Disorder
- Complex PTSD
- Learned Helplessness
- Chronic Stress Syndrome
- Insomnia Disorder
- Substance Use Disorders
- Chronic Pain Disorders
- Cognitive Fatigue Syndrome
- Emotional Numbing Syndrome
DIAGNOSTIC CONSIDERATIONS
Core Diagnostic Features
Individuals commonly demonstrate:
- Depressed mood and/or loss of interest or pleasure
- Symptoms present most of the day, nearly every day
- Significant distress or functional impairment
- Associated cognitive, emotional, physical, and behavioral symptoms
- Symptoms not better explained by another medical or psychiatric condition
Differential Considerations
Condition | Distinguishing Feature |
Persistent Depressive Disorder | More chronic, lower-grade depressive symptoms |
Bipolar Disorder | History of mania or hypomania |
Adjustment Disorder | Symptoms linked to a specific stressor and generally less severe |
Bereavement | Grief-related symptoms predominate |
Hypothyroidism | Medical etiology drives symptoms |
Neurocognitive Disorders | Cognitive decline predominates |
SCF THERAPEUTIC MECHANISMS
SCF-PCR PREVENTATIVE
Objectives
- Strengthen resilience
- Reduce chronic stress burden
- Preserve neuroplasticity
- Enhance emotional regulation
- Promote social connectedness
SCF-PCR CURATIVE
Therapeutic Targets
Mood Regulation Layer
- Emotional stabilization
- Negative-affect reduction
- Positive-affect restoration
Reward Layer
- Anhedonia reduction
- Motivation restoration
- Reward responsiveness enhancement
Neuroplasticity Layer
- Synaptic resilience enhancement
- Adaptive learning restoration
- Cognitive flexibility improvement
Cognitive Layer
- Rumination reduction
- Cognitive restructuring
- Self-efficacy restoration
Social Layer
- Social engagement restoration
- Relationship strengthening
- Community reintegration
SCF-PCR RESTORATIVE
Functional Restoration Goals
- Symptom remission
- Functional recovery
- Cognitive restoration
- Occupational resilience
- Emotional wellbeing
- Long-term relapse prevention
CURRENT EVIDENCE-BASED TREATMENT APPROACHES
Psychological Interventions
Primary Approaches
- Cognitive Behavioral Therapy (CBT)
- Behavioral Activation Therapy
- Interpersonal Therapy (IPT)
- Acceptance and Commitment Therapy (ACT)
- Mindfulness-Based Cognitive Therapy
- Psychodynamic Psychotherapy
Therapeutic Objectives
- Reduce depressive symptoms
- Improve coping skills
- Restore behavioral engagement
- Prevent relapse
Pharmacologic Interventions
Common evidence-based pharmacologic classes include:
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
- Atypical antidepressants
- Tricyclic antidepressants (selected cases)
- Other guideline-supported antidepressant therapies
Treatment selection should be individualized based on symptom profile, comorbidities, prior treatment response, and safety considerations.
Neuromodulation Approaches
When clinically appropriate:
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Electroconvulsive Therapy (ECT)
- Other emerging neuromodulation strategies
PROGNOSIS
Prognosis is influenced by:
- Severity of illness
- Episode duration
- Treatment adherence
- Psychiatric comorbidities
- Social support
- Chronic stress burden
- Medical comorbidities
- Access to evidence-based care
Many individuals achieve significant improvement or remission with comprehensive treatment. Early intervention and sustained management substantially improve long-term outcomes.
SCF THERAPEUTIC MECHANISMS (SCF-PCR BRAID)
Preventative
- Resilience enhancement
- Stress reduction
- Sleep optimization
- Social-support strengthening
Curative
- Mood restoration
- Reward-system normalization
- Neuroplasticity enhancement
- Cognitive restructuring
Restorative
- Functional recovery
- Relapse prevention
- Quality-of-life restoration
- Long-term emotional resilience
PROJECT RHENOVA — INTEGRATION PATHWAYS
Research Axis 1
Multi-omic characterization of depressive phenotypes and treatment-response subtypes.
Research Axis 2
Neuroplasticity, inflammation, and depression biomarker discovery programs.
Research Axis 3
Reward-network and mood-regulation connectomics mapping.
Research Axis 4
Stress–neuroplasticity–depression interaction pathway modeling.
Research Axis 5
Precision therapeutic frameworks for depressive-spectrum disorders.
NEXT STRATEGIC RESEARCH PATHWAYS
- Depression biomarker discovery programs.
- Neuroplasticity and synaptic-resilience investigations.
- Reward-circuit connectomics studies.
- Neuroimmune–mood interaction pathway characterization.
- Mitochondrial and neuroenergetic dysfunction research.
- Digital phenotyping of depressive trajectories.
- AI-assisted relapse and treatment-response prediction systems.
- Precision psychiatry biomarker development.
- Personalized neuromodulation optimization studies.
- Functional outcome endpoint development for Major Depressive Disorder prevention, treatment, remission, and recovery.
INDEX — SCF-RDOS-MDD-001
Registry Code: SCF-RDOS-MDD-001
Indication: Major Depressive Disorder
Domain: Depressive Disorders
Framework Version: SCF-RDOS Mood Disorders Registry v1.0
Classification Tier: Depressive Spectrum Disorder
Research Status: Translational Characterization Candidate
Document Type: SCF Pathophysiology and Therapeutic Development Blueprint
Registry Position: MDD-001-2026